Nicotinic acetylcholine receptor alpha-4 beta-2 (α4β2 nAChR) (α4β2 nAChR)

The Nicotinic acetylcholine receptor alpha-4 beta-2 (α4β2 nAChR) is a pentameric ligand-gated ion channel that serves as the predominant high-affinity nicotinic receptor subtype in the mammalian central nervous system (Gotti et al., 2006, PMID: 17030136). It is primarily composed of α4 and β2 subunits, typically arranged in (α4)2(β2)3 or (α4)3(β2)2 stoichiometries, which dictate its sensitivity to agonists and calcium permeability (Moroni et al., 2006, PMID: 16714417). This receptor plays a pivotal role in modulating the release of neurotransmitters such as dopamine, glutamate, and GABA, thereby influencing reward pathways, attention, and memory (Albuquerque et al., 2009, PMID: 19126755). Due to its high affinity for nicotine, it is the principal mediator of nicotine dependence and a primary target for smoking cessation pharmacotherapies like varenicline (Rollema et al., 2007, PMID: 17303142). Beyond addiction, α4β2 receptors are implicated in the pathophysiology of Alzheimer's disease, Parkinson's disease, and certain forms of epilepsy, making them significant targets for cognitive enhancers and neuroprotective agents (Picciotto et al., 2008, PMID: 18297054). Therapeutic development focuses on subtype-selective partial agonists and positive allosteric modulators to minimize off-target effects on peripheral nicotinic receptors (Taly et al., 2009, PMID: 19543217).

Other names

Alpha-4 beta-2 nicotinic receptorCHRNA4/CHRNB2 complexNeuronal acetylcholine receptor alpha-4 beta-2α4β2 nicotinic acetylcholine receptorHigh-affinity nicotinic receptor

The α4β2 nAChR functions as a ligand-gated cation channel; upon binding of acetylcholine or nicotine, the channel undergoes a conformational change to an open state, allowing the influx of Na+ and Ca2+ ions (Albuquerque et al., 2009, PMID: 19126755). This depolarization triggers the release of various neurotransmitters, most notably dopamine in the mesolimbic pathway, which mediates the reinforcing effects of nicotine (Rollema et al., 2007, PMID: 17303142). Drugs like varenicline act as partial agonists, providing enough stimulation to reduce withdrawal symptoms while blocking the full effect of nicotine (Coe et al., 2005, PMID: 16134936).